Adaptive Biotechnologies (ADPT) Other Non-Current Liabilities (2019 - 2026)

Adaptive Biotechnologies has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $20000.0 for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $20000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $20000.0 (changed 0.0% YoY), and the FY2025 annual result was $20000.0, changed 0.0% from the prior year.
• Other Non-Current Liabilities came in at $20000.0 for Q1 2026 at Adaptive Biotechnologies, roughly flat from $20000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $128.2 million in Q2 2023 to a low of $20000.0 in Q2 2024.
• The 5-year median for Other Non-Current Liabilities is $20000.0 (2024), against an average of $42.1 million.
• Across the five-year window, Other Non-Current Liabilities slumped 99.98% in 2024 and changed 0.0% in 2025, its largest moves.
• Adaptive Biotechnologies' Other Non-Current Liabilities stood at $125.4 million in 2022, then advanced by 2.24% to $128.2 million in 2023, then plunged by 99.98% to $20000.0 in 2024, then changed by 0.0% to $20000.0 in 2025, then changed by 0.0% to $20000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $20000.0 (Q1 2026), $20000.0 (Q4 2025), and $20000.0 (Q3 2025), per Business Quant data.